ArticleMedicine2018
Shen-Ling-Bai-Zhu-San for ulcerative colitis: Protocol for a systematic review and meta-analysis.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Herbal Formula Shenling Baizhu San for Chronic Diarrhea in Adults: A Systematic Review and Meta-analysis.Integrative cancer therapiesPooled it
- A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis.European journal of nutrition · 2021Trial
- The HARP (Hemoglobin-Albumin-C-Reactive Protein) Index: A Biologically Designed Composite Biomarker for Continuous Prognostic Modeling in Locally Advanced Nasopharyngeal Carcinoma.Diseases (Basel, Switzerland) · 2026Article
- Investigating the Therapeutic Mechanisms of Shen-Ling-Bai-Zhu-San in Type 2 Diabetes and Ulcerative Colitis Comorbidity: A Network Pharmacology and Molecular Simulation Approach.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Downregulation of MT2-MMP and MT5-MMP in ulcerative colitis serves a diagnostic predictor and potential therapeutic targets.Molecular biology reports · 2025Article
- Traditional Chinese Medicines as Effective Reversals of Epithelial-Mesenchymal Transition Induced-Metastasis of Colorectal Cancer: Molecular Targets and Mechanisms.Frontiers in pharmacology · 2022Review
- Shen-Ling-Bai-Zhu-San Enhances the Antipneumonia Effect of Cefixime in Children by Ameliorating Gut Microflora, Inflammation, and Immune Response.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms.Frontiers in pharmacology · 2022Review
- Clinical characteristics and impacts of traditional Chinese medicine treatment on the convalescents of COVID-19.International journal of medical sciences · 2021Article
- Traditional Chinese Medicine Enhances Survival in Patients with Gastric Cancer after Surgery and Adjuvant Chemotherapy in Taiwan: A Nationwide Matched Cohort Study.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.BMC complementary medicine and therapies · 2020Article
- Shen-Ling-Bai-Zhu-San Improves Dextran Sodium Sulfate-Induced Colitis by Inhibiting Caspase-1/Caspase-11-Mediated Pyroptosis.Frontiers in pharmacology · 2020Article
- Huangkui Lianchang Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting the NF-kappaB Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) at the colonic mucosa and submucosa. Shen-Ling-Bai-Zhu-San (SLBZS) is one of the most common formulations of traditional Chinese medicine (TCM) for the treatment of UC. However, its effects and safety remain uncertain. This protocol is described for a systematic review to investigate the beneficial effects and safety of SLBZS for UC.
methodsWe will systematically search for eligible studies in PubMed, the Cochrane library, Embase, the Chinese Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI), and Wanfang Data (WAN FANG) until August 2018. The primary outcomes are the induction of remission and the maintenance of remission. The summary results will be pooled using the random-effects model or fixed-effects model according to the heterogeneity of the included studies.
resultsThe results will be submitted to a peer-reviewed journal for publication.
conclusionThe conclusion of our systematic review will provide evidence to judge whether SLBZS is an effective intervention for patient with UC. PROSPERO REGISTRATION NUMBER: PROSPERO CRD 42018100477.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.